Patients & Caregivers

Agios Clinical Trials

Agios has leveraged its core capabilities in cellular metabolism to build a product engine that is focused in the therapeutic areas of cancer and rare genetic disorders of metabolism.

DISEASE PROGRAM STUDY PHASE STATUS LEARN MORE
Acute Myeloid Leukemia ENASIDENIB or IVOSIDENIB Phase 1b Safety Study of Ivosidenib or Enasidenib in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation Active, not recruiting clinicaltrials.gov
Acute Myeloid Leukemia ENASIDENIB or IVOSIDENIB Phase 1/2 Safety and Efficacy Study of Oral Ivosidenib Plus Subcutaneous Azacitidine and Oral Enasidenib Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Recruiting clinicaltrials.gov
Acute Myeloid Leukemia IVOSIDENIB Phase 1 Study of Orally Administered Ivosidenib in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Active, not recruiting clinicaltrials.gov
Acute Myeloid Leukemia IVOSIDENIB Phase 3 Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) Recruiting clinicaltrials.gov
Acute Myeloid Leukemia IVOSIDENIB Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation Available clinicaltrials.gov
Solid Tumors (including Glioma) IVOSIDENIB Phase 1 Study of Orally Administered Ivosidenib in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation Active, not recruiting clinicaltrials.gov
Cholangiocarcinoma IVOSIDENIB Phase 3 Study of Orally Administered Ivosidenib in Previously Treated Advanced Cholangiocarcinoma Patients With IDH1 Mutations (ClarIDHy) Recruiting clinicaltrials.gov
claridhy.com
Solid Tumors (including Glioma) AG-881 Phase 1 Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation Active, not recruiting clinicaltrials.gov
Glioma IVOSIDENIB or AG-881 Perioperative Study of AG-120 and AG-881 in Subjects With Low Grade Glioma Recruiting clinicaltrials.gov
Advanced Solid Tumors or Lymphoma AG-270 Phase 1 Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss Recruiting clinicaltrials.gov
Pyruvate kinase deficiency Mitapivat Phase 2 DRIVE PK Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency Active, not recruiting clinicaltrials.gov
drivepktrial.com
Pyruvate kinase deficiency Pyruvate Kinase Deficiency Global Longitudinal Registry (PEAK Registry) Recruiting clinicaltrials.gov
Pyruvate kinase deficiency Mitapivat Phase 3 Study (ACTIVATE-T) Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Recruiting clinicaltrials.gov
Pyruvate kinase deficiency Mitapivat Phase 3 Study (ACTIVATE) to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Not yet recruiting clinicaltrials.gov

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.